Lenti-Dual-iCas9-CMV
(Plasmid
#167500)
-
PurposeExpression of dual inducible Cas9 with CMV promoter
-
Depositing Lab
-
Sequence Information
Ordering
This material is available to academics and nonprofits only.
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 167500 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
Backbone
-
Vector backboneLenti-iCas9-neo
- Backbone size w/o insert (bp) 10000
- Total vector size (bp) 15206
-
Vector typeMammalian Expression, Lentiviral, CRISPR, Luciferase
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameCas9
-
SpeciesH. sapiens (human)
-
Insert Size (bp)4509
- Promoter CMV
-
Tag
/ Fusion Protein
- FLAG (C terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer Unknown
- 3′ sequencing primer Unknown (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Lenti-Dual-iCas9-CMV was a gift from Jake Liang (Addgene plasmid # 167500 ; http://n2t.net/addgene:167500 ; RRID:Addgene_167500) -
For your References section:
A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells. Park SB, Uchida T, Tilson S, Hu Z, Ma CD, Leek M, Eichner M, Hong SG, Liang TJ. Mol Ther Nucleic Acids. 2022 Apr 27;28:656-669. doi: 10.1016/j.omtn.2022.04.013. eCollection 2022 Jun 14. 10.1016/j.omtn.2022.04.013 PubMed 35615005
